Biopharmaceuticals
Oncology
News Release - October 2, 2006
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy
Source: Roche
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.